Kyowa Hakko Kirin Group Introduces IV Treatment and Companion Diagnostic
This article was originally published in PharmAsia News
Executive Summary
The Kyowa Hakko Kirin Group announced on May 7 the sale of Poteligeotest IHC as a companion diagnostic to the intravenous Poteligeo (mogamulizumab).